About
CARDIOSOLV™: A NEW PARADIGM FOR VT ABLATION CardioSolv™ is an early stage company developing new strategies to improve the treatment of patients with Ventricular Tachycardia (VT), a life-threatening arrhythmia. Using proprietary software and algorithms, CardioSolv™ develops a patient-specific model that guides VT ablation therapy with the goal of improving patient outcomes while reducing procedure time and cost.
Technologies
Remote
Company Information
-
Employees 1
-
Founded 2012
-
Annual Revenue $310000
-
Total Funding $52000
Location
2443 Maryland Ave, Baltimore, Maryland, United States, 21218-5018
